Inpharma Weekly

, Volume 1553, Issue 1, pp 15–15 | Cite as

Topotecan + paclitaxel: promising response, tolerability in advanced NSCLC

Clinical study
  • 4 Downloads

Keywords

Lung Cancer Survival Rate Paclitaxel Partial Response Multicentre Trial 

Copyright information

© Adis International Ltd 2006

Personalised recommendations